scholarly journals Long-Term Survival Analysis of Adjuvant Chemotherapy with or without Trastuzumab in Patients with T1, Node-Negative HER2-Positive Breast Cancer

2019 ◽  
Vol 25 (24) ◽  
pp. 7388-7395 ◽  
Author(s):  
Xuexin He ◽  
Jiali Ji ◽  
Mei Tian ◽  
Francisco J. Esteva ◽  
Gabriel N. Hortobagyi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Survival Analysis ◽  
Adjuvant Chemotherapy ◽  
Her2 Positive ◽  
Term Survival ◽  
Node Negative ◽  
Long Term Survival ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Long-term Survival after Lapatinib Rechallenge in Isolated Brain Metastasis of HER2-positive Breast Cancer

2015 ◽  
Vol 11 (1) ◽  
pp. 48-51
Author(s):  
Bulent Karagoz ◽  
Alpaslan Ozgun ◽  
Levent Emirzeoglu ◽  
Tolga Tuncel ◽  
Serkan Celik ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Brain Metastasis ◽  
Her2 Positive ◽  
Term Survival ◽  
Long Term Survival ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Real-World Outcomes of Adjuvant Chemotherapy for Node-Negative and Node-Positive HER2-Positive Breast Cancer

2019 ◽  
Vol 17 (1) ◽  
pp. 47-56 ◽  
Author(s):  
Zachary Veitch ◽  
Omar F. Khan ◽  
Derek Tilley ◽  
Domek Ribnikar ◽  
Xanthoula Kostaras ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Real World ◽  
Her2 Positive ◽  
Node Negative ◽  
Node Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Long-term survival in a young woman with recurrent HER2-positive breast cancer.

ABOUTOPEN ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. 29-31
Author(s):  
Gianluca Cotroneo
Keyword(s):  
Breast Cancer ◽  
Disease Control ◽  
Young Woman ◽  
Tumor Recurrence ◽  
Therapeutic Strategies ◽  
Her2 Positive ◽  
Term Survival ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

We report the case of a patient with HER2-positive breast cancer relapsing after 7 years from diagnosis with a HER2-positive tumor recurrence, treated with anti-HER2 drugs (pertuzumab, trastuzumab and lapatinib) associated to radiotherapy and/or chemotherapy. These therapeutic strategies allowed satisfactory disease control after about 4 years from recurrence (Oncology).

scholarly journals Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer

2015 ◽  
Vol 372 (2) ◽  
pp. 134-141 ◽  
Author(s):  
Sara M. Tolaney ◽  
William T. Barry ◽  
Chau T. Dang ◽  
Denise A. Yardley ◽  
Beverly Moy ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Her2 Positive ◽  
Node Negative ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals Long-term trastuzumab (Herceptin®) treatment in a continuation study of patients with HER2-positive breast cancer or HER2-positive gastric cancer

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Volkmar Müller ◽  
Michael Clemens ◽  
Jacek Jassem ◽  
Nedal Al-Sakaff ◽  
Petra Auclair ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gastric Cancer ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

scholarly journals The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?

2020 ◽  
Vol 20 (6) ◽  
pp. 503-510
Author(s):  
Haiping Lin ◽  
Hongjuan Zheng ◽  
Chenyang Ge ◽  
Qinghua Wang ◽  
Wanfen Tang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Treatment ◽  
Her2 Positive ◽  
Node Negative ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer
Sign in / Sign up

Export Citation Format

Share Document